Thus, these studies indicate that treatment with insulin, SGLT2i or incretin-based therapy could improve glycocalyx dimensions measured by use of the GlycoCheck system in type 2 diabetes. The gene discussed is GCG; the disease is type 2 diabetes mellitus.